Evolus (EOLS) Non-Current Assets (2017 - 2026)
Evolus' (EOLS) quarterly Non-Current Assets came in at $81.7 million in Q1 2026, little changed YoY from $81.6 million in Q1 2025, and down 1.48% on a QoQ basis from $83.0 million in Q4 2025.
Evolus (EOLS) Non-Current Assets (2017 - 2026) Analysis & Trends
Evolus (EOLS) has 10 years of Non-Current Assets data on file, last reported at $81.7 million in Q1 2026.
- Quarterly Non-Current Assets changed 0.1% year-over-year to $81.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $332.6 million (up 4.68% YoY) and the FY2025 annual result came in at $83.0 million, up 2.12% from the prior year.
- Non-Current Assets slipped to $81.7 million in Q1 2026, from $83.0 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $84.1 million in Q3 2025 to a low of $72.5 million in Q2 2023.
- A 5-year average of $78.6 million and a median of $77.2 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets dropped 5.78% — and 2025, when it grew 10.83%.
- Tracing EOLS's Non-Current Assets over 5 years: stood at $77.2 million in 2022, then dropped by 0.78% to $76.6 million in 2023, then grew by 6.07% to $81.2 million in 2024, then grew by 2.12% to $83.0 million in 2025, then dropped by 1.48% to $81.7 million in 2026.
- The last three Non-Current Assets figures came in at $81.7 million (Q1 2026), $83.0 million (Q4 2025), and $84.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Evolus | 552.49 Mn | 507.32 Mn | 57.18 Mn | 80.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80.48 Mn |
| Mar 31, 2026 | 81.72 Mn |
| Dec 31, 2025 | 82.95 Mn |
| Sep 30, 2025 | 84.11 Mn |
| Jun 30, 2025 | 83.83 Mn |
| Mar 31, 2025 | 81.64 Mn |
| Dec 31, 2024 | 81.23 Mn |
| Sep 30, 2024 | 79.25 Mn |
| Jun 30, 2024 | 75.64 Mn |
| Mar 31, 2024 | 75.91 Mn |
| Dec 31, 2023 | 76.58 Mn |
| Sep 30, 2023 | 75.97 Mn |
| Jun 30, 2023 | 72.52 Mn |
| Mar 31, 2023 | 76.15 Mn |
| Dec 31, 2022 | 77.18 Mn |
| Sep 30, 2022 | 76.77 Mn |
| Jun 30, 2022 | 76.97 Mn |
| Mar 31, 2022 | 77.73 Mn |
| Dec 31, 2021 | 78.68 Mn |
| Sep 30, 2021 | 76.88 Mn |